cdk8-in-10

CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.

CDK8 19-IN-3 (compound 3-7) is a potent and selective inhibitor of CDK8 and CDK19. It can increase IL-10 levels and has potential for research in inflammatory bowel disease (IBD).

CDK8-IN-5, a potent inhibitor of CDK8 with an inhibitory concentration (IC 50) of 72 nM, demonstrates anti-inflammatory properties and achieves a 43% enhancement rate of IL-10. This compound holds potential for inflammatory bowel disease research.

CDK8-IN-15 (Compound 46) is a potent inhibitor of CDK8, exhibiting an IC50 value of 57 nM. This compound enhances the thermal stability of CDK8 and inhibits NF-κB, while selectively targeting the CDK family and tyrosine kinases. Additionally, it actively counteracts TNF-α-induced psoriasis in vitro and boosts the expression of Foxp3 and IL-10, potentially diminishing inflammatory responses and showing promise for research into psoriasis treatments.